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Summary Transgenic mice carrying the activated rat c-neu oncogene under transcriptional control of the
MMTV promoter were backcrossed to BALB/c mice, with the aim of developing a model for cancer therapy.
A total of 86 of 268 transgene-positive mice in the first five generations developed 93 histologically diverse
tumours (median age of onset 18 months). The cumulative incidence of breast tumours at 24 months was 18%,
and overall tumour incidence 31%. As well as expected c-neu expressing breast cancers, lymphomas and
Harderian gland carcinomas developed. Virgin mice had fewer mammary tumours than those with two litters.
Breast carcinomas metastasised to the lungs, and lymphomas were widely disseminated. The tumours showed
a range of architectural patterns, which resembled human breast cancers or lymphomas. This diversity was
reflected in S-phase fraction and aneuploidy. Breast tumours transplanted to nude mice showed variable
responses to interferon (IFN)-a and T. A tumour transplanted to BALB/c mice responded to interleukin
(IL)-12. There was significant decline in transgene positivity with successive generations. The diversity,
histological and biological resemblance to human cancer suggests that the model has potential for evaluating
novel therapies. However, further genetic and environmental manipulations are required to increase tumour
incidence and decrease age of onset.
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Existing murine tumour models have a number of disadvan-
tages that limit their usefulness in the investigation of cancer
therapy, particularly cytokine therapy. Some syngeneic
tumours are immunogenic and when treated with cytokines
an allograft response may predominate. Transplantable
tumours are often derived from cell lines and produce rapidly
growing tumours that are a model for poorly differentiated
or anaplastic tumours. Such tumours are not analogous to
those human malignancies that respond to cytokines and also
may not develop the complex host-tumour relationship of
slow growing tumours. Similar disadvantages apply to
models of metastases. Human tumour xenografts growing in
nude mice are obviously inappropriate for studying any
cytokine that may act via the host immune system. Conse-
quently, there is a need for a murine tumour system that
more closely resembles human cancer, is metastatic and arises
in an immunocompetent animal. A model that also reflects
the diversity of growth patterns encountered in human car-
cinomas, and uses an oncogene implicated in a particular
cancer, would have further advantages.
Human c-erbB-2, the human equivalent of the rodent neu
oncogene, was found to be amplified in 30% of 189 primary
human breast cancers (Slamon et al., 1987). This
amplification had greater predictive value in lymph node-
positive disease than existing prognostic factors. In both
invasive, and certain types of in situ carcinoma, a high
cytological grade was associated with up-regulation of this
gene. In particular, comedo-type ductal carcinoma was a
histological type of tumour more frequently associated with
c-erbB-2 amplification (Van de Vijver et al., 1988). This gene
is therefore an appropriate candidate in a model tumour
system. There are two well-characterised transgenic mouse
models of mammary cancer that possess the activated neu
oncogene under control of the MMTV-promoter (Muller et
al., 1988; Bouchard et al., 1989). In the model of Muller et
al., tumours arise synchronously in all mice, involve the
entire gland and are polyclonal in origin. In the neu trans-
genic mice developed by Bouchard et al., tumours are
monoclonal and appear later, in a stochastic pattern, in
approximately 30-50% of mated female mice (Bouchard et
al., 1989). Because of its closer resemblance to the biology of
human disease, we have used the latter model to establish a
colony of inbred mice. In this paper we describe the range of
tumours, their morphology, biological diversity, metastatic
pattern and growth characteristics. We compare these
features with the similar data available on c-erbB-2-positive
human mammary carcinoma. To enable a preliminary assess-
ment of the potential of these mice as a model for cancer
therapy, we have established eight tumours from the colony
in nude mice or transgene-negative mice and treated these
with a range of cytokines.
Materials and methods
Mice
Three male founder mice on a C57B1/6 x C3H background
were obtained from Professor Paul Jolicoeur. These had been
generated by microinjecting a 8.2 kb SacII-EcoRI chimeric
DNA fragment containing the activated rat c-neu cDNA
under transcriptional control of the MMTV long terminal
repeat (LTR) (Bouchard et al., 1989). One-cell embryos were
collected, microinjected and transferred into pseudopregnant
CD-1 females (Hogan et al., 1986). Transgene-positive female
mice have now been backcrossed onto inbred BALB/c males
for eight generations. Inbred BALB/c mice were obtained
from ICRF breeding unit, Clare Hall, South Mimms, Hert-
fordshire. All mice studied were housed in the specified
pathogen-free unit at Clare Hall from birth until tumour
development or death from other causes. Female nu/nu mice
of mixed genetic background were obtained from the ICRF
breeding unit and maintained in negative pressure isolators.
Tumours were implanted in mice aged 6-8 weeks.
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Screening and colony
Screening for the transgene was established initially using
Southern hybridisation analysis of tail DNA using a neu-Oncogene transgenic mice as cancer models
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specific 4.6 kb probe which has the HindlII-Sall digest from
the microinjected DNA fragment. This did not hybridise to
tailsnip DNA from transgene negative C57 B1/6 and BALB/c
mice. Once back-checking had been performed, slot-blotting
was established using 10fig of DNA per slot and the 4.6 kb
probe, labelled with 32P. In the first six generations positive
females were placed 'at risk' of tumour development by
mating them against BALB/c mice for two litters.
Histopathology
Morphological analysis The animals were inspected for
general condition and tumours at least twice a week. If the
animals became unwell, or tumours ulcerated or approached
2 cm in diameter, they were sacrificed and a post mortem
examination performed. In most cases only one tumour was
evident at this point. Tumour tissue, lungs, liver and spleen
were fixed in neutral buffered formalin (NBF) and embedded
in paraffin wax. Parallel samples were also snap frozen.
Immunohistochemistry Sections were immunostained with
an antibody to human c-erbB-2 (1:50 dilution) (Dakopatts,
Denmark) and in the case of lymphomas, the murine T/B
lineage antibodies to oc/PTCR(1:1000 dilution) (Pharmingen,
USA), B220(1:300 dilution) (Pharmingen, USA), Surface
Ig(1:25 dilution) (Sigma, USA) and Thy 1.2(1:100 dilution)
(Becton-Dickinson, USA). These antibodies were employed
in conjunction with a standard streptavidin-biotin technique.
A brown reaction product was obtained using a peroxidase
substrate [diaminobenzidine, phosphate-buffered saline (PBS)
0.3% hydrogen peroxide]. All antibodies except Thy 1.2
worked well and appropriately on formalin-fixed material
after prior microwaving of the sections. For microwaving the
unstained sections were immersed in 0.01 M sodium citrate
buffer solution at pH 6 in which they were microwaved at
700 W for 10 min with rapid cooling by running water
thereafter to avoid deleterious drying. The antibody to Thy
1.2 worked without microwaving sections. All histopathology
assessment was performed by a consultant pathologist with
an interest in breast cancer (AMH). A human mammary
carcinoma known to be positive for human c-erbB-2 was
used as a positive control for the c-erbB-2 antibody. Mouse
lymph node and tonsillar tissue, in which there are distinct
patterns of T and B lymphocyte localisation, acted as both
positive and negative controls for the murine T and B lineage
markers.
Tumour growth andflow cytometric analysis Flow cytometry
was performed on nuclear suspensions prepared from
formalin-fixed paraffin-embedded sections as described else-
where (Camplejohn et al., 1989). Three 50jm paraffin sec-
tions were dewaxed and rehydrated through a series of
alcohols into double distilled water. Nuclei were extracted by
the addition of pepsin (5 mgml-') at 37°C for 30 min at pH
1.5. Following filtration through a 35 mm pore size nylon
filter and incubation with 250 mg ml-' of propidium iodide,
the samples were analysed using a Becton-Dickinson FACS
Analyser powered by a mercury arc lamp. Approximately 105
particles were scanned to construct a DNA histogram. The
DNA index was calculated by relating DNA content of the
aneuploid GO/GI peak to that for the diploid GO/G, peak.
The S-phase fraction (SPF) for the diploid tumours was
measured using the method of Baisch et al. (1975). The
number of cells in S-phase was calculated from a rectangle
fitted between the peak channels of the GO/GI and G2/M
peaks. For the DNA aneuploid histogram the percentage of
aneuploid S-phase cells as a percentage of total aneuploid
cells was estimated in a similar way (Camplejohn et al.,
1989).
Cytokine therapy As a result of the incompletely defined
mode of action of most cytokines and the apparent lack of a
dose-response relationship in many studies, both clinical and
animal studies have attempted to define the optimal mode of
administration and regimen. A comparison of the toxicity of
anti-cancer agents in mouse, rat, hamster, dog, monkey and
man was devised based on a formula in which surface area to
volume ratios between species were taken into account
(Freireich et al., 1966). Using Freireich's formula we have
used a dose of 5 x 104 U per animal per day of both rh
interferon (IFN)-a A/D hybrid and rat IFN-y, equivalent to
a dose of 11 x 106 U per day in a human. In each case the
mice were injected with 0.05 ml of tumour on day 0 and
treatment with control diluent or cytokines commenced on
day 7, and continued for 42 days, or less if the animal was
unwell. FN-a A/D hybrid was the kind gift of Dr Michael
Brunda, Hoffmann La Roche, New Jersey USA. Recom-
binant rat IFN-y was the kind gift of Roussel UCLAF,
Romainville, France. Recombinant murine interleukin (IL)-
12 was the kind gift of Dr Brunda and was used at a dose of
1 ytg per animal per day.
Results
Overall tumour incidence in transgene-positive animals
A total of 86 of 268 female mice in these first five generations
developed 93 histologically diverse tumours over a period of
25 months. Of these 83 arose in tissues known to express the
transgene. Fifty-three breast carcinomas, 24 Harderian gland
tumours, six lymphomas and five vascular tumours developed
as well as five of less common histological types. The median
age of tumour development was 18 months. At 24 months
the cumulative incidence of breast tumours was 18%, with an
incidence of 34% for all tumour types. The development of
the three major tumour types in this colony is shown in
Figure 1 and Table I. Four mice developed two different
histological tumour types simultaneously. Consequently
tumour incidence is based on number of mice succumbing as
a result of tumours and not on numbers of tumours.
Tumour incidence in successive generations
Analysis of the second, third and fourth generation showed a
slight decline in the median age of tumour development
(17,15 and 15 months respectively). The proportion of
tumours that were of mammary origin remained the same.
Change in transgene positivity with successive generation
A total of 738 female mice were bred onto a BALB/c back-
ground in the first seven generations, of which 391 were
transgene positive. There was a gradual and significant dec-
line in the proportion of transgene-positive females born with
each successive generation (Figure 2). This observation was
originally based on slot-blot results but was confirmed by
Southern blotting. The difference between the generations
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Figure 1 Age at onset of three major tumour types in colony.
M, mammary; FO1, Harderian gland; _, lymphoma.
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5gave a x2 value of 9.097, with 2 degrees of freedom (d.f.),
P= 0.01. Looking for a trend, given that the proportion
appeared to be declining, the test for trend value was
X2= 20.6, d.f. = 1, P<0.001. This suggests that there is not
only a difference between the generations but this difference
is occurring in a particular direction. The transgene was
transmitted normally when homozygous matings were estab-
lished and litter number and offspring viability of the
homozygous mice was the same as in heterozygotes. How-
ever, in the heterozygous matings there were fewer transgene-
positive offspring than expected with successive generations
and sometimes whole litters were transgene negative.
Influence oflitter number on tumour development
The influence of litter number on tumour development was
studied in the fourth generation. Virgin mice developed fewer
mammary tumours, those mice mated only once developed
no mammary tumours whereas those mated two or more
times had a higher incidence of tumours overall (Figure 3).
There was an overall difference between the groups in rela-
tion to litter number, (P = 0.003 by Fisher's exact test).
Comparing the incidence of mammary tumours between the
groups is also statistically significant (P = 0.006, Fisher's
exact test). It appears that the risk of a mammary tumour
development is not increased by further litters.
Pathological description oftumours
Mammary carcinomas Of the 93 tumours, 53 were mam-
mary (57%). Phenotypically they were characterised by a
subcutaneous tumour in an otherwise well animal. The age at
onset ranged from 10 to 25 months, with a median of 15
months. These tumours all shared high-grade cytomor-
phology with a high degree of mitotic activity and pleomor-
phism. No definite in situ carcinoma was seen. The architec-
tural pattern showed a range of appearances with the follow-
ing types of growth pattern merging one with another and
sometimes co-existing in the same tumour. These patterns
were generally as follows:
(1) Tumours showing islands of interlocking large cells with
areas of necrosis, characteristic of the classical comedo-
type tumours described by Bouchard et al. (1989) in the
founder mice and associated with c-erbB-2 positivity.
Unlike human comedo carcinoma, characterised by a
large cell ductal carcinoma in situ with central necrosis,
the tumours were not confined to ducts (Figure 4a).
(2) Solid tumours in which sheets and well-defined islands of
tumour were present but no large areas of necrosis.
(3) Tumours which were completely or partly (micro) papil-
lary in nature. Though a minor component of four of the
tumours, in a further eight tumours this was the
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Figure 2 Percentage of females born transgene positive in the
first seven generations. The difference between the generations:
c2value of 9.097, with 2 degrees of freedom (d.f.), P= 0.01.
Chi-squared test for trend value was c2 = 20.6, d.f. = 1, P<0.001.
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predominant growth pattern (Figure 4b). Pure tumours
of this type consisted of numerous duct-like structures, in
which the malignant epithelium contained therein was
thrown into small papillae. The number of these struc-
tures considerably exceeded the number of ducts nor-
mally expected and it was deduced that the appearances
represented invasive disease. In two tumours some of the
papillary growth pattern was contained within a cystic
space thus architecturally (but not cytologically) mimick-
ing human intracystic papillary carcinoma.
(4) In one tumour a spindle cell epithelial element was seen
evolving from more typical solid-type carcinoma in keep-
ing with a so-called 'metaplastic' carcinoma. A further
tumour was entirely of metaplastic type.
None of the tumours showed a significant host
inflammatory response and all of the tumours stained
positively with an antibody to human c-erbB-2. Though this
was occasionally patchy and included much diffuse cytoplas-
mic staining, convincing appropriate membrane staining was
demonstrated in all 53 tumours.
Twenty-three of the 53 (43%) mammary tumours metas-
tasised to lung (an example is shown in Figure 4c). Lymph
node deposits were sometimes seen near the primary site and
carcinoma cells were also seen in the liver sinusoids and the
spleen. No metastases were recorded in bone. However these
were sought by sectioning spinal cord in 20 of the mice. In
humans, the more sensitive technique of bone scintigraphy
would normally be used. Of the spectrum of pathology, the
micropapillary histological pattern appeared most likely to
metastasise to lung, with an incidence of 11/16 (69%) as
compared with 12/37(32%) of the non-papillary tumours
(P = 0.003, Fisher's exact test).
Harderian gland carcinomas The Harderian gland is a
modified sebaceous gland found deep in the orbit of animals
with a nictitating membrane. Twenty-four Harderian gland
carcinomas were seen, being diagnosed mainly on the basis of
a protruberant eye and the presence of fluid and solid
tumour behind the eye at post-mortem. Age of onset ranged
from 11 to 25 months with median being 18 months. In four
cases lung metastases were found on pathological assessment,
although no primary was noted post-mortem. Histologically
these tumours were papillary in pattern and resembled the
more poorly differentiated end of the spectrum found to
occur naturally (see Figure 4d). There was a higher propor-
tion of these tumours in virgin mice than in mated mice.
Sixty per cent of Harderian gland carcinomas metastasised to
lung. Metastases did not appear to correlate with the grade
of the primary tumour. Indeed, in one case, the primary
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Figure 3 Influence of litter number on mammary tumour
development. Overall difference between the groups in relation to
litter number, P = 0.003, Fisher's exact test. Comparing the
incidence of mammary tumours between the groups was also
statistically significant, P = 0.006, Fisher's exact test. _, Total
tumours; MI, mammary tumours.
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tumour had the appearance of an adenoma but metastases in
the lungs were consistent with a malignant Harderian gland
carcinoma. There was a statistically significant difference
(P = 0.003) between the proportion of Harderian gland
tumours metastasising to lung in mated mice as compared
with the proportion arising in virgin mice (Table II). All the
24 Harderian gland tumours stained positively for c-erbB-2.
Lymphomas Six malignant lymphoid tumours arose in the
transgenic mice under observation in this colony. All were
disseminated at post mortem examination. Microscopically
the spleen, liver and lungs were diffusely infiltrated. One
lymphoma appeared to arise in the calvarium and subse-
quently disseminated into the brain and systemically. In
other cases lymphoma was found to be infiltrating the spine,
lung, large intestine and skin. The age at onset ranged from 4
to 21 months, with a median of 17.5 months. In one case the
tumour had the morphology of an immunoblastic lymphoma
with lymphoplasmacytoid features, while the rest manifested
as a lymphoblastic lymphoma/acute lymphoblastic leukaemia
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Figure 4 Histology of tumours in transgene-positive females (a) Comedo-type mammary tumour. n, area of necrosis. (b)
Papillary-type mammary tumour. (c) Lung metastasis (m) from mammary carcinoma. (d) Harderian gland carcinoma. (e)
Lymphoblastoid lymphoma. (f) Angiosarcoma, arrows mark blood vessels.
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(Figure 4e). All six lymphomas demonstrated a B-cell
phenotype using the four murine antibodies against o./p TCR,
Thy 1.2, surface IgG and B220. They also stained positively
with the antibody to c-erbB-2.
Vascular tumours In five mice vascular tumours were seen,
of which three were undoubted angiosarcomas (Figure 4f)
and the other two suggestive of angiosarcoma. These
tumours were present in a variety of sites and were evident
macroscopically as very vascular, with obvious blood-filled
spaces. One involved the spleen, another was attached to a
pedicle arising from the bladder base and another appeared
to derive from subcutaneous tissue overlying the neck. In two
mice tumour was found in the spleen as well as another site.
Two arose in conjunction with Harderian gland carcinomas.
None of these stained positively with an antibody to c-erbB-2.
Others In total there were five other tumours. One meta-
plastic carcinoma of uncertain site of origin, one spindle cell
sarcoma, not otherwise specified, one tumour resembling a
papillary mesothelioma morphologically and two adenocar-
cinomas in which the lung appeared to be the primary site.
None of these tumours stained positively with an antibody to
c-erbB-2.
S-phasefraction analysis
In order to confirm the subjective impression of diversity in
this model, both within and between tumour subcategories,
we have examined their proliferative rate using S-phase frac-
tion. Thirteen primary mammary tumours were examined
and 11 found to exhibit a wide range of S-phase fraction
(range 5.6-11.9, median 9.0). In two other mammary
tumours there were two clones of tumour preventing analysis
of the S-phase fraction of the different aneuploid peaks. One
of the 13 mammary tumours was diploid and 12 were aneup-
loid. Analysis of both aneuploidy and S-phase fraction was
possible in 9 of the 13 tumours and these data are shown in
Figure 5. Two primary lymphomas were also examined and
the S-phase fraction values were 6.1 and 13.9.
Transplantation oftumours into BALBIc mice
Three attempts at tumour transplantation from second and
third generation mice into other mice of the colony failed.
However, one tumour from the fourth generation, which
arose in a 13-month-old female mouse, has been successfully
passaged. The tumour arose over the left shoulder in the
mammary line and there were no other abnormalities at
post-mortem examination. Injected into the flank of two
offspring, it became established after about 16 weeks and was
then passaged into other mice from the same litters. By
passage 3 it was found to grow readily in ordinary BALB/c
mice. Histologically this was a mammary tumour with a
comedo-type pattern and extensive areas of necrosis. No
metastases have been seen at post mortem examination to
date. This tumour has been further passaged successfully and
has been used in preliminary cytokine therapy experiments as
described below.
IL-12 therapy oftransplanted tumour
Aliquots of 0.05 ml of this murine mammary carcinoma were
injected into two groups of eight female BALB/c mice on day
0. Injection with control diluent or rmIL-12 daily was com-
menced on day 7, for a total period of 42 days. The cytokine
appeared to be well tolerated. Tumours grew in all control-
injected mice, but only six of eight IL-12 injected mice.
Median survival of the control and treated groups was 32
and 70 days respectively. (Log-rank survival, x2 P = 0.01)
Two IL-12-injected mice were still alive with no evidence of
tumour some 233 days later (Figure 6).
Interferon sensitivity of tumours transplanted into nude mice
further demonstrates biological diversity
Seven of seven mammary tumours were successfully trans-
planted and passaged in nude mice. We have examined the
anti-tumour activity of two interferons in these transplants.
Interferon-cr A/D hybrid, a recombinant human hybrid
molecule with strong activity on murine cells (Rehberg et al.,
1982) was used because it is more readily available than
purified murine IFN-x. The other cytokine used, recombinant
rat IFN-y, also has cross-species specificity. Figure 7 shows
the percentage change in survival of IFN-treated mice com-
pared with a group of control diluent-treated mice. The
animals were killed when the tumour size reached 2 cm, or
on the basis of factors such as poor health of the animal. In
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Figure 5 S-phase fraction and DNA index in nine spontaneously
arising tumours in the colony. _, DNA index; M1, SPF
(S-phase fraction).
Table I Tumour development in transgenic mice
Number of Median age of C-erbB-2
Tumour Type tumours (O%) onset (range) positivity
Mamary carcinoma 53 (57) 15.0 (10-25) +
Harderian gland 24 (26) 18.0 (14-25) +
carcinoma 6 (6) 17.5 (4-21) +
Lymphoma
Angiosarcoma 4 (4) 22.5 (21 -24)
Others 6 (6) 19.0 (14-25)
Table 1I Metastasis of Harderian gland tumours
Virgin Mated Total
Number of Harderian gland 6/53 18/187 24/240
tumours
Number with lung metastases 1 16 17
Percentage with lung metastases 16.7% 88.8% 70.8%
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Figure 6 Percentage increase in survival of nude mice bearing
transplanted breast tumours and receiving interferon therapy.
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Figure 7 Percentage increase in survival of nude mice bearing
transplanted breast tumours and receiving interferon therapy.
_, IFN-a; = IFN-7; , IFN-a + IFN-y.
each group seven or eight animals were assessable and
median survival for the group calculated.
There was a marked diversity between different tumours in
their sensitivity to the individual interferons and their com-
bination. With one exception, all the cytokine-treated
animals survived longer (but not always statistically so) than
control diluent treated. IFN-a treatment caused a significant
increase in survival in two of seven different tumour lines
(P = 0.003), IFN-y in three of seven (P = 0.02, P = 0.003,
P = 0.001) and IFN-o/y combinations in three of seven
(P = 0.001 or P = 0.003). Three of the tumours failed to
respond significantly to either IFN or their combination.
Two of the tumours responded significantly to both IFN-x
and y, and in only one case did the combination of these
work in the absence of a response to the individual cytokine.
Discussion
The rationale for this study was to develop a model for use
in preclinical assessment of cancer therapy, in particular
cytokine therapy. An unexpectedly diverse range of tumour
types and biological behaviours has been observed. The
founder mice were reported to develop poorly differentiated
metastatic adenocarcinomas of the breast at 7-14 months of
age in a stochastic and asynchronous fashion (Bouchard et
al., 1989). As these mice have been backcrossed onto a
BALB/c background for eight successive generations, the
tumour incidence has been lower and the tumour types have
been more varied and have arisen later than in the founder
mice (Thomas and Balkwill, 1994). This may be the result of
the BALB/c background, but may also have been affected by
differences in animal husbandry, diet, endemic infection and
relative crowding of the animals in the two colonies. In this
particular model tumours arise after a number of genetic
events and all the above factors may contribute.
One notable observation was the decline in transgene
positivity with successive generations. Any explanation for
this is likely to be complex. It may be that the transgene is
not inherited or expressed as a result of the abnormal 'state'
of the oncogene in these mice. As a result it may not be
feasible to maintain a reproducible and stable model using a
colony of transgenic mice. This potential drawback for the
assessment of therapy could be overcome by homozygous
matings. This is our current strategy now that the colony has
reached the eleventh generation. Another option may be to
use a different inbred mouse, such as FVB, which is more
suitable for microinjection of DNA, and is more amenable to
tumour development. There is no apparent change in the
expression or structure of the transgene being transmitted on
the basis of Southern analysis with three different enzymes.
Similarly protein expression has not altered on the basis of
immunohistochemical analysis of transgene-positive tumours
from different generations. The change in transgene transmis-
sion may be explained by a disadvantage to the heterozygous
mice that results in death in utero.
Of the two mammary tumour transgenic models involving
MMTV-activated neu, the tumours described by Bouchard et
al. (1989) bore a greater histological resemblance to human
mammary tumours than those described by Muller et al.
(1988). We have seen this characteristic morphology in 35 of
the 47 mammary tumours. This bears some resemblance to
the histological pattern seen in large-cell or comedo-type
DCIS in humans, a histological type of tumour associated
with c-erbB-2 amplification (Bartkova et al., 1990). Features
of papillary carcinoma, present to varying degrees in twelve
of the tumours, are also consistent with findings in humans
and associated with c-erbB-2 positivity. The close similarities
between the grade and cytopathology of murine mammary
cancer associated with c-neu and the human disease assoc-
iated with c-erbB-2, is in contrast with those seen in other
mammary tumours in oncogene transgenic mice (Halter et
al., 1992; Cardiff et al., 1993).
The resemblance to human tumours also extends to many
of the non-mammary tumours arising in the colony. Lym-
phomas have previously been described in mice transgenic for
the normal human c-erbB-2 oncogene (Suda et al., 1990).
These lymphomas were predominantly B cell in origin. All
the lymphomas in our colony stained positively with the
antibody to c-erbB-2 and were B cell in origin, suggesting
that they were related to expression of the transgene. There
were five angiosarcomas arising at a number of different sites
that did not express the transgene. In the mouse angiosar-
comas usually arise in the spleen, liver and subcutaneous
tissues, although they account for fewer than 3% of spon-
taneously arising tumours (Smith and Pilgrim, 1971).
Angiosarcomas tend to be locally invasive and may metas-
tasise to the lungs. This suggests these tumours may not be
related to transgene expression, although the incidence is
rather high, angiosarcomas being rare in BALB/c mice.
Neoplasms of the Harderian gland form a spectrum and
the vast majority arising spontaneously in BALB/c mice
tumours are categorised as adenomas. A few progress to
adenocarcinomas and metastasise to lung, although the
incidence of metastases may be increased by exposure to a
number of mutagens and chemicals (Della Porta et al., 1963;
Fry et al., 1975; Vesselinovitch et al., 1975). In our
experience Harderian gland carcinomas frequently metas-
tasised to lung in mice that had two litters, but not in virgin
mice. This did not appear to correlate with the grade of the
primary tumour, which is comparable with the behaviour of
spontaneously arising carcinomas. The Harderian gland car-
cinomas stained positive for c-erbB-2.
The incidence of mammary tumours arising spontaneously
in BALB/c mice kept in germ-free conditions varies widely in
different studies. They appear to have a relatively low
incidence of spontaneous mammary tumours (up to 5% in
retired breeding females) (Foster et al., 1982). Other sources
suggest up to 3% in breeding females and 1% in virgin mice
(Smith and Pilgrim, 1971; Kalra et al., 1993) during the
normal lifespan of the mouse. The incidence of spontaneous
lymphomas in BALB/c mice kept in germ-free conditions is
less than 3% but again the overexpression of neu suggests
that the transgene is involved. The median S-phase fraction
value for murine mammary carcinomas arising in this colony
is similar to that of human mammary carcinomas (9.0% in
these tumours; 9.6% in humans) (Camplejohn et al., 1995). A
higher proportion of the murine tumours were aneuploid
than in many human series (11/12 in this study as compared
with 18/29 human tumours in Kalra et al. (1993)) but this is
entirely consistent with the poor differentiation of these
tumours, and characteristic of their neu positivity.
The unactivated neu oncogene has been reported to be
associated with the development of mammary tumours thatOncogene transgenic mice as cancer models
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metastasise to lung in older transgenic mice (Guy et al., 1992)
but the activated gene has been linked with aggressive
primary tumours with a relatively low incidence of metastasis
(Muller et al., 1988; Bouchard et al., 1989). In our model, in
tumours approaching the 2 cm diameter limit, the incidence
of metastases approached 70%, being similar to that seen
with the unactivated neu oncogene and making this a useful
model for the study of metastasis. This is most likely a
consequence of the BALB/c genetic background and the fact
that tumours arise later in this model in comparison with the
founder mice of Bouchard et al. (1989).
Our findings with this colony have not been described by
others working with mice transgenic for activated c-neu.
Indeed the spectrum of tumours more closely resembles that
described by Suda et al. (1990) in mice with the unactivated
c-erbB-2 oncogene and that seen with MMTV-Ha-ras
(Cardiff et al., 1993). The c-neu proto-oncogene (rat
homologue of the human c-erbB-2 oncogene) is a membrane-
bound 185 kDa receptor molecule with tyrosine kinase
activity. It shares partial homology with the epidermal
growth factor receptor and its role in mammary cancer has
been extensively investigated (Slamon et al., 1987). In a
chemically transformed neuroblastoma cell line, rat c-neu is
activated by a point mutation, which results in a single
amino-acid substitution (valine to glutamic acid) in the trans-
membrane domain of the protein (Bargmann et al., 1986a).
The mutant neu gene, but not the normal neu gene, can
transform NIH3T3 cells (Bargmann et al., 1986b). Substitu-
tion of the corresponding amino acid in human c-erbB-2
protein would require two mutations in the gene. The human
c-erbB-2 gene can transform the fibroblasts by overexpression
(Di Fiore et al., 1987). Overexpression of c-erbB-2 and not
activation is found in human adenocarcinomas, particularly
breast and stomach cancers (Yokota et al., 1986; Van der
Vijver et al., 1987).
The breast tumours arising in the colony grew readily in
nude mice and such transplants were used in preliminary
cytokine therapy experiments. The aim of these experiments
was to develop treatment schedules that could be translated
to spontaneously arising tumours at a later date; to assess the
inherent cytokine sensitivity of these tumours and to assess
the inter-tumour variation in response. In general IFN
therapy had a modest beneficial effect on survival but the
response was not dramatic and only two complete regressions
were recorded in over 150 treated tumours. Three of the
tumour lines failed to respond significantly to either IFN or
their combination. This lack of response is similar to the
human experience with these cytokines in solid tumours
(Sparano and O'Boyle, 1992). The diversity of response of
individual tumours is again analogous to results obtained in
clinical trials with several cytokines (Gutterman, 1994).
Recombinant murine IL-12 has been tested against a
number of murine tumour models (Brunda et al., 1993) and
shown to have potent in vivo anti-tumour and anti-metastatic
effects. The preliminary results were encouraging and cer-
tainly warrant further investigation. IL-12 would seem to be
the most suitable candidate for treatment of spontaneous
tumours in this model.
To date there has been limited use of transgenic mice for
preclinical assessment of cancer therapy. One of the few
studies involved the use of chemotherapy in hybrid trans-
genic mice (Dexter et al., 1993). However the histopathology
of the tumours was not comparable with that seen in
humans.
In summary, this model, which demonstrates a histological
and biological convergence of human and murine mammary
cancer, has potential for evaluating the spectrum of cancer
therapies and as such is highly relevant to the assessment of
novel therapies for c-erbB-2-positive breast cancer. However
further manipulations, such as dietary change, hormonal
therapy or administration of mild carcinogens, are required
to increase the incidence, and decrease the age of onset, of
tumours in the colony.
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